Evaluation and Comparison of Citalopram and Venlafaxine for
                    Management of Hot Flashes in Women with Breast Cancer

Sasan Yaghoobi Taleghani; Farnaz Etesam; Mohsen Esfandbod

doi:10.1055/a-2061-7020

Drug Research, Table of Contents

Drug Res (Stuttg) 2023; 73(08): 465-472
DOI: 10.1055/a-2061-7020

Original Article

Evaluation and Comparison of Citalopram and Venlafaxine for Management of Hot Flashes in Women with Breast Cancer

Sasan Yaghoobi Taleghani

¹School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

²Department of Clinical Hematology Oncology and Bone Marrow Transplantation, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

,

Farnaz Etesam

³Department of Psychiatry, Psychosomatic Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

,

Mohsen Esfandbod

²Department of Clinical Hematology Oncology and Bone Marrow Transplantation, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

› Author Affiliations

Abstract

Background Breast cancer is the most common cancer in women worldwide. Premature menopause and hot flashes are the main complications of breast cancer treatments. About 40 to 50 percent of breast cancer women who undergo chemotherapy are experiencing premature menopause symptoms, including hot flashes. Some endocrine therapies such as tamoxifen and aromatase inhibitors are associated with induction or aggravating hot flashes. Hot flashes are often debilitating and significantly impair daily functions. Therefore many therapeutic options have been studied so far for the management of this adverse effect. However, there are still some clinical challenges in managing hot flashes in patients with breast cancer.

Objective We aimed to evaluate and compare the efficacy of venlafaxine and citalopram on hot flashes in breast cancer women receiving tamoxifen.

Design We conducted a double-blind, placebo-controlled trial in forty-one, 35 to 65 years old female patients. The study lasted for four weeks, and the follow-up was for two months. Venlafaxine and citalopram treatments started with doses of 37.5 mg or 10 mg, respectively. Venlafaxine and citalopram dosages were increased in the second week to 75 and 20 mg, respectively. The study was conducted during the year 2017.

Key Results The results indicated that the total efficacy was significantly different in groups receiving citalopram, venlafaxine, and placebo. Total efficacy in the placebo group, venlafaxine, and citalopram was 14.3, 53.8, and 64.3%, respectively (p=0.02). During the second week, the efficacy in groups receiving citalopram, venlafaxine, and placebo was 57.1, 53.8, and 14.3%, respectively (p=0.04). Generally, both citalopram and venlafaxine were well tolerated. The associated adverse effects were mild to moderate in both groups.

Conclusions Although citalopram was associated with more adverse effects, including constipation, it was more effective in reducing the frequency of hot flashes when compared to venlafaxine or placebo.

Key words

breast cancer - citalopram - hot flash - premature menopause - venlafaxine

Full Text

References

References
1 World Health Organization. International agency for research on cancer. Available at: https://gco.iarc.fr
2 DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s cancer: Principles & Practice of Oncology (Cancer Principles and Practice of Oncology) 11th Edition.
3 NCCN guidelines. Available at: https://www.nccn.org/guidelines
4 Ramaswami R, Villarreal MD, Pitta DM. et al. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2015; 152: 231-237
5 Morrow PK, Mattair DN, Hortobagyi GN. Hot flashes: a review of pathophysiology and treatment modalities. Oncologist 2011; 16: 1658-1664
6 Barton DL, Ganz PA. Symptoms: Menopause, Infertility, and Sexual Health. Adv Exp Med Biol 2015; 862: 115-141
7 Fisher WI, Johnson AK, Elkins GR. et al. Risk factors, pathophysiology, and treatment of hot flashes in cancer. CA Cancer J Clin 2013; 63: 167-192
8 Pachman DR, Jones JM, Loprinzi CL. Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions. Int J Womens Health 2010; 2: 123-135
9 Dalal S, Zhukovsky DS. Pathophysiology and management of hot flashes. J Support Oncol 2006; 4: 315-320
10 Ladd CO, Newport DJ, Ragan KA. et al. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depress Anxiety 2005; 22: 94-97
11 Barton D, Loprinzi C, Wahner-Roedler D. Hot flashes: aetiology and management. Drugs Aging 2001; 18: 597-606
12 Loprinzi CL, Sloan J, Stearns V. et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol 2009; 27: 2831-2837
13 Guthrie KA, Larson JC, Ensrud KE. et al. Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials. Sleep. 2018; 41: zsx190
14 Kaplan M, Mahon S. Hot flash management: update of the evidence for patients with cancer. Clin J Oncol Nurs 2014; 18: 59-67
15 Wiśniewska I, Jochymek B, Lenart-Lipińska M. et al. The pharmacological and hormonal therapy of hot flushes in breast cancer survivors. Breast Cancer 2016; 23: 178-182
16 Mallhi TH, Khan YH, Khan AH. et al. Managing Hot Flushes in Menopausal Women: A Review. J Coll Physicians Surg Pak 2018; 28: 460-465
17 Eden J. ENDOCRINE DILEMMA: Managing menopausal symptoms after breast cancer. Eur J Endocrinol 2016; 174: R71-R77
18 Toulis KA, Tzellos T, Kouvelas D. et al. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. Clin Ther 2009; 31: 221-235
19 Handley AP, Williams M. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. J Am Assoc Nurse Pract 2015; 27: 54-61
20 Loibl S, Schwedler K, von Minckwitz G. et al. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients – a double-blind, randomized study. Ann Oncol 2007; 18: 689-693
21 Sideras K, Loprinzi CL. Nonhormonal management of hot flashes for women on risk reduction therapy. J Natl Compr Canc Netw 2010; 8: 1171-1179
22 Leon-Ferre RA, Majithia N, Loprinzi CL. Management of hot flashes in women with breast cancer receiving ovarian function suppression. Cancer Treat Rev 2017; 52: 82-90
23 Faubion SS, Loprinzi CL, Ruddy KJ. Management of Hormone Deprivation Symptoms After Cancer. Mayo Clin Proc 2016; 91: 1133-1146
24 Bordeleau L, Pritchard K, Goodwin P. et al. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin Ther 2007; 29: 230-241
25 Pinkerton JV, Santen RJ. Managing vasomotor symptoms in women after cancer. Climacteric. 2019; 22: 544-552
26 Ruddy KJ, Loprinzi CL. Antidepressants decrease hot flashes and improve life quality. Menopause. 2015; 22: 587-588
27 Caan B, LaCroix AZ, Joffe H. et al. Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial. Menopause. 2015; 22: 607-615
28 Shams T, Firwana B, Habib F. et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med 2014; 29: 204-213
29 Stubbs C, Mattingly L, Crawford SA. et al. Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women. J Okla State Med Assoc 2017; 110: 272-274
30 Berhan Y, Berhan A. Is desvenlafaxine effective and safe in the treatment of menopausal vasomotor symptoms? A meta-analysis and meta-regression of randomized double-blind controlled studies. Ethiop J Health Sci 2014; 24: 209-218
31 Irarrázaval OME, Gaete GL. Elección del mejor antidepresivo en pacientes con cáncer de mama en tratamiento con tamoxifeno: revisión de la evidencia básica y clínica [Antidepressants agents in breast cancer patients using tamoxifen: review of basic and clinical evidence]. Rev Med Chil 2016; 144: 1326-1335 Spanish
32 Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009; 70: 1688-1697
33 Caraci F, Crupi R, Drago F. et al. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab 2011; 12: 570-577
34 Boekhout AH, Vincent AD, Dalesio OB. et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2011; 29: 3862-3868
35 Davari-Tanha F, Soleymani-Farsani M, Asadi M. et al. Comparison of citalopram and venlafaxine’s role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial. Arch Gynecol Obstet 2016; 293: 1007-1013
36 Barton DL, Loprinzi CL, Novotny P. et al. Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol 2003; 1: 47-51
37 Ladd CO, Newport DJ, Ragan KA. et al. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depress Anxiety 2005; 22: 94-97
38 Biglia N, Torta R, Roagna R. et al. Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas. 2005; 52: 78-85
39 Azizi M, Khani S, Kamali M. et al. The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials. Iran J Med Sci 2022; 47: 173-193
40 L’Espérance S, Frenette S, Dionne A. et al. Comité de l’évolution des pratiques en oncologie (CEPO). Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer 2013; 21: 1461-1474